参考文献/References:
[1] Cui Y, Wan Q. NKT cells in neurological diseases [J]. Front Cell Neurosci, 2019, 13: 245-251.
[2] Gerth E, Mattner J. The role of adaptor proteins in the biolo-gy of natural killer T (NKT) cells [J]. Front Immunol, 2019,10: 1449-1453.
[3] Cerundolo V, Barral P, Batista FD. Synthetic iNKT cell-agonists as vaccine adjuvants--finding the balance [J]. Curr Opin Immunol, 2010, 22(3): 417-424.
[4] McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity [J]. Cancer Immunol Res, 2015, 3(5): 425-435.
[5] Dempsey LA. NKT cells aid antiviral responses [J]. NatImmunol, 2018, 19(2): 99-103.
[6] 赵炜熠，初 明. 胶质瘤免疫抑制与治疗的研究进展[J]. 中国临床神经外科杂志，2018，23（3）：212-214.
[7] Dashtsoodol N, Shigeura T, Tashiro T, et al. Natural killer T cell-targeted immunotherapy mediating long-term memory responses and strong antitumor activity [J]. Front Immunol,2017, 8: 1206-1211.
[8] Nair S, Dhodapkar MV. Natural killer T cells in cancer im-munotherapy [J]. Front Immunol, 2017, 8: 1178-1181.
[9] Lindau D, Gielen P, Kroesen M, et al. The immunosuppres-sive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells [J]. Immunology,2013, 138(2): 105-115.
[10] Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells[J]. Adv Immunol, 2014, 122: 91-128.
[11] Mackay A, Burford A, Molinari V, et al. Molecular, patholo-gical, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase Ⅱrandomized trial [J]. Cancer Cell, 2018, 33(5): 829-842.
[12] Wolf BJ, Choi JE, Exley MA. Novel approaches to exploiting invariant NKT cells in cancer immunotherapy [J]. Front Immunol, 2018, 9: 384-389.
[13] Liu D, Song L, Brawley VS, et al. Medulloblastomaexpresses CD1d and can be targeted for immunotherapy with NKT cells [J]. Clin Immunol, 2013, 149(1): 55-64.
[14] Chong TW, Goh FY, Sim MY, et al. CD1d expression inrenal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival [J]. J Clin Pathol, 2015, 68(3): 200-205.
[15] Borg NA, Wun KS, Kjer-Nielsen L, et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor [J]. Nature, 2007, 448(7149): 44-49.
[16] Gebremeskel S, Clattenburg DR, Slauenwhite D, et al. Natu-ral killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice [J]. Onco Immunol, 2015, 4(3): e55-62.
[17] Marsh JC, Goldfarb J, Shafman TD, et al. Current status of immunotherapy and gene therapy for high-grade gliomas [J]. Cancer Control, 2013, 20(1): 43-48.
[18] Ghinnagow R, De Meester J, Cruz LJ, et al. Co-delivery of the NKT agonist alpha-galactosylceramide and tumor anti-gens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses [J]. OncoImmunol, 2017, 6(9): 33-38.
[19] Hunn MK, Hermans IF. Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines [J]. OncoImmunol, 2013, 2(4): 78-89.
[20] Tang B, Wu W, Wei X, et al. Activation of glioma cellsgenerates immune tolerant NKT cells [J]. J Biol Chem, 2014, 289(50): 34595-34600.
相似文献/References:
[1]付 锴 江普查 宫 睿 王 伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(11):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳 琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫 珊 徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(11):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮 夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(11):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民 褚会松 田 甜 王昆鹏 杨国军 杨立军 王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(11):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述 王 辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰 姚庆和 李晓辉 龙宇波 陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(11):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘 靖 吴立权 黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(11):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘 炎 杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明 胡新华 刘 永 陈 玖 刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]